"Budget control Act of 2011"
Washington, DC
The budget control Act of 2011 has been signed into Law.
In the House of Representatives, U. S.,
August 1, 2011.
Resolved, That the bill from the Senate (S. 365) entitled
"An Act to make a technical amendment to the Education
Sciences Reform Act of 2002.", do pass with the following:
AMENDMENT:
Strike all after the enacting clause and insert the
following:
1 SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
2 (a) SHORT TITLE.—This Act may be cited as the
3 "Budget Control Act of 2011".
The following link will take you to the 74 page document.
http://www.gpo.gov/fdsys/pkg/BILLS-112s ... 365eah.pdf
The budget control Act of 2011 has been signed into Law.
In the House of Representatives, U. S.,
August 1, 2011.
Resolved, That the bill from the Senate (S. 365) entitled
"An Act to make a technical amendment to the Education
Sciences Reform Act of 2002.", do pass with the following:
AMENDMENT:
Strike all after the enacting clause and insert the
following:
1 SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
2 (a) SHORT TITLE.—This Act may be cited as the
3 "Budget Control Act of 2011".
The following link will take you to the 74 page document.
http://www.gpo.gov/fdsys/pkg/BILLS-112s ... 365eah.pdf
COPD Trial Stopped After Excess Deaths
COPD Trial Stopped After Excess Deaths
Washington DC
The Department of Veterans Affairs halted an experimental disease management program for chronic obstructive pulmonary disease after excess deaths were seen in a randomized trial. The trial, called BREATH (Bronchitis and Emphysema Advice and Training to Reduce Hospitalizations), was intended to determine if intensive patient education and personalized management for patients with COPD would reduce hospitalizations and readmissions. The trial began in 2006 with a one-year pilot study and was enlarged to 22 sites the following year. The trial was stopped with less than half of the originally projected number of participants. BREATH was originally planned to enroll 960 patients but only 413 had been enrolled when the trial was halted because of an increased death rate in the intervention arm of the study. The trial included a control group that received only the standard care. All participants were veterans already under treatment for COPD within the VA system. Patients already in the study in 2009 have continued under observation and the VA has indicated that a manuscript is being prepared for submission to a peer-reviewed journal.
A prior VA study published in the American Journal of Respiratory and Critical Care Medicine 2010;182:890-896 (Oct 1) concluded that “A relatively simple disease management program did reduced hospitalizations and emergency department (ED) visits for COPD” ... Continue to Full Story
Washington DC
The Department of Veterans Affairs halted an experimental disease management program for chronic obstructive pulmonary disease after excess deaths were seen in a randomized trial. The trial, called BREATH (Bronchitis and Emphysema Advice and Training to Reduce Hospitalizations), was intended to determine if intensive patient education and personalized management for patients with COPD would reduce hospitalizations and readmissions. The trial began in 2006 with a one-year pilot study and was enlarged to 22 sites the following year. The trial was stopped with less than half of the originally projected number of participants. BREATH was originally planned to enroll 960 patients but only 413 had been enrolled when the trial was halted because of an increased death rate in the intervention arm of the study. The trial included a control group that received only the standard care. All participants were veterans already under treatment for COPD within the VA system. Patients already in the study in 2009 have continued under observation and the VA has indicated that a manuscript is being prepared for submission to a peer-reviewed journal.
A prior VA study published in the American Journal of Respiratory and Critical Care Medicine 2010;182:890-896 (Oct 1) concluded that “A relatively simple disease management program did reduced hospitalizations and emergency department (ED) visits for COPD” ... Continue to Full Story
New Members to House Veterans’ Affairs Committee
Washington, D.C. —
U.S. Rep. Jeff Miller (R-Florida), the Chairman-elect of House Veterans’ Affairs Committee has announced six new Members to the committee for the 112th Congress.
The new Republicans selected for the House Veterans’ Affairs Committee include (in alphabetical order):
Dan Benishek – Michigan
Ann Marie Buerkle – New York
Jeff Denham – California
Tim Huelskamp -- Kansas
Bill Johnson – Ohio
Jon Runyan – New Jersey
View the entire committee at:
http://veterans.house.gov/about/Membership.asp
U.S. Rep. Jeff Miller (R-Florida), the Chairman-elect of House Veterans’ Affairs Committee has announced six new Members to the committee for the 112th Congress.
The new Republicans selected for the House Veterans’ Affairs Committee include (in alphabetical order):
Dan Benishek – Michigan
Ann Marie Buerkle – New York
Jeff Denham – California
Tim Huelskamp -- Kansas
Bill Johnson – Ohio
Jon Runyan – New Jersey
View the entire committee at:
http://veterans.house.gov/about/Membership.asp
House VA Committee Vice-Chair & Subcommittee Chairs
WASHINGTON DC
Congressman Jeff Miller (FL-01), chairman of the House Committee on Veterans Affairs, announced the majority vice-chairman of the full committee and the subcommittee chairs for the 112th Congress.
The Majority caucus approved the following vice-chairman and subcommittee chairs:
Vice-Chairman of the Full Committee, Congressman Gus Bilirakis (FL-09)
Chairwoman of the Subcommittee on Health, Congresswoman Ann Marie Buerkle (NY-25)
Chairman of the Subcommittee on Oversight and Investigations, Congressman Bill Johnson (OH-06)
Chairman of the Subcommittee on Disability Assistance and Memorial Affairs, Congressman Jon Runyan (NJ-03)
Chairman of the Subcommittee on Economic Opportunity, Congressman Marlin Stutzman (IN-03)
Congressman Jeff Miller (FL-01), chairman of the House Committee on Veterans Affairs, announced the majority vice-chairman of the full committee and the subcommittee chairs for the 112th Congress.
The Majority caucus approved the following vice-chairman and subcommittee chairs:
Vice-Chairman of the Full Committee, Congressman Gus Bilirakis (FL-09)
Chairwoman of the Subcommittee on Health, Congresswoman Ann Marie Buerkle (NY-25)
Chairman of the Subcommittee on Oversight and Investigations, Congressman Bill Johnson (OH-06)
Chairman of the Subcommittee on Disability Assistance and Memorial Affairs, Congressman Jon Runyan (NJ-03)
Chairman of the Subcommittee on Economic Opportunity, Congressman Marlin Stutzman (IN-03)
HEALTH CARE NEWS
Washington, DC
New NIH study projects survivorship and costs of cancer care will increase to $207 billion based on changes in the US population and cancer trends. The analysis appears online, Jan. 12, 2011, in the Journal of the National Cancer Institute.
Based on growth and aging of the U.S. population, medical expenditures for cancer in the year 2020 are projected to reach at least $158 billion (in 2010 dollars) — an increase of 27 percent over 2010, according to a National Institutes of Health analysis. The projections were based on the most recent data available on cancer incidence, survival, and costs of care. In 2010, medical costs associated with cancer were projected to reach $127.6 billion, with the highest costs associated with breast cancer ($16.5 billion), followed by colorectal cancer ($14 billion), lymphoma ($12 billion), lung cancer ($12 billion) and prostate cancer ($12 billion).
If cancer incidence and survival rates and costs remain stable and the U.S. population ages at the rate predicted by the U.S. Census Bureau, direct cancer care expenditures would reach $158 billion in 2020, the report said.
These new projections are higher than previously published estimates of direct cancer expenditures, largely because the researchers used the most recent data available — including Medicare claims data through 2006, which include payments for newer, more expensive, targeted therapies which attack specific cancer cells and often have fewer side effects than other types of cancer treatments. In addition, by analyzing costs according to phase of care, which revealed the higher costs of care associated with the first year of treatment and last year of life (for those who die from their disease), the researchers were able to generate more precise estimates of the cost of care. ... Continue to Full Story
New NIH study projects survivorship and costs of cancer care will increase to $207 billion based on changes in the US population and cancer trends. The analysis appears online, Jan. 12, 2011, in the Journal of the National Cancer Institute.
Based on growth and aging of the U.S. population, medical expenditures for cancer in the year 2020 are projected to reach at least $158 billion (in 2010 dollars) — an increase of 27 percent over 2010, according to a National Institutes of Health analysis. The projections were based on the most recent data available on cancer incidence, survival, and costs of care. In 2010, medical costs associated with cancer were projected to reach $127.6 billion, with the highest costs associated with breast cancer ($16.5 billion), followed by colorectal cancer ($14 billion), lymphoma ($12 billion), lung cancer ($12 billion) and prostate cancer ($12 billion).
If cancer incidence and survival rates and costs remain stable and the U.S. population ages at the rate predicted by the U.S. Census Bureau, direct cancer care expenditures would reach $158 billion in 2020, the report said.
These new projections are higher than previously published estimates of direct cancer expenditures, largely because the researchers used the most recent data available — including Medicare claims data through 2006, which include payments for newer, more expensive, targeted therapies which attack specific cancer cells and often have fewer side effects than other types of cancer treatments. In addition, by analyzing costs according to phase of care, which revealed the higher costs of care associated with the first year of treatment and last year of life (for those who die from their disease), the researchers were able to generate more precise estimates of the cost of care. ... Continue to Full Story
by news | Wednesday, August 3, 2011 at 1:41 PM
Be the first to post a comment!